Evidence map›Paper›PMID 42520189›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Selective and Potent First-in-Class CRBN-Dependent Molecular Glue Degraders of WW Domain-Binding Protein 4.

Yuhang Liu, Lu Chen, Bo Peng, Pingping Zeng, Linhui Cao, Lu Huang, Lixin Zhou, Shuke Yang, Jun Wang, Yanli Sun and 8 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yuhang LiuSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, China; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China.
Lu ChenDepartment of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, China.
Bo PengLingang Laboratory, Shanghai, China.
Pingping ZengDepartment of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, China.ORCID 0009-0009-1446-6569
Linhui CaoSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, China; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China.
Lu HuangGuangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Lixin ZhouDepartment of Hematology, Tongji Hospital, Frontier Science Center For Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.ORCID 0009-0007-2519-7929
Shuke YangLingang Laboratory, Shanghai, China.
Jun WangLingang Laboratory, Shanghai, China.ORCID 0000-0003-2585-5614
Yanli SunLingang Laboratory, Shanghai, China.
Lu ChenLingang Laboratory, Shanghai, China.
Yixuan FengLingang Laboratory, Shanghai, China.ORCID 0009-0001-3111-2828
Taiting ShiLingang Laboratory, Shanghai, China.
Qi ChenLingang Laboratory, Shanghai, China.
Kehao ZhaoSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, China; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China.
Jing LuSchool of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, China; Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China.ORCID 0000-0001-9195-7470
Baishan JiangDepartment of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, China.ORCID 0000-0001-6796-9500
Wenchao LuLingang Laboratory, Shanghai, China.ORCID 0000-0003-1175-365X

Funding

Fundamental Research Funds for the Central Universities 2042022dx0003National Key R&D Program of China 2025YFA1309000Shanghai Pujiang Talent Program 23PJ1430100
6 · The paper itself

Abstract

Targeted protein degradation via molecular glues represents a powerful modality for modulating "undruggable" proteins. Herein, through proteomic profiling of a CRBN-binding library and rigorous structure-activity relationship (SAR) refinement, we report the discovery of dWBP4-1: a first-in-class, highly selective, CRBN-dependent molecular glue degrader of the spliceosome-associated scaffold protein WBP4. dWBP4-1 induces rapid, nanomolar degradation of WBP4 via a canonical G-loop-mediated mechanism, exhibiting exceptional proteome-wide selectivity with negligible transcriptomic or alternative splicing perturbation. Leveraging this highly specific target-glue interaction, we mapped the minimal WBP4 degron to a 41-amino-acid sequence to establish a compact, inducible chemical-genetic platform termed wTAG. When fused to diverse proteins of interest, wTAG enables robust, monotonic degradation devoid of the hook effect. While the wTAG system is highly versatile, we delineate its boundaries when applied to challenging targets like Cyclin D1, where factors such as steric hindrance, lysine availability, complex sequestration, and tag accessibility (N- vs. C-terminal fusion) must be carefully interrogated. Collectively, this study highlights the discovery of a highly selective WBP4 molecular glue and translates its underlying degron into a robust tool for precise protein control.

Indexed as

Adaptor Proteins, Signal TransducingUbiquitin-Protein LigasesDegronsHumansProteolysisStructure-Activity RelationshipWW DomainsAdaptor Proteins, Signal TransducingCRBN protein, humanUbiquitin-Protein Ligasesmolecular glue degraderscaffold proteintargeted protein degradationWBP4wTAG

Identifiers

PMID42520189
PMCPMC13573099

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.